Pyxis Oncology Inc PYXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Trading Information
- Previous Close Price
- $1.61
- Day Range
- $1.65–1.70
- 52-Week Range
- $1.04–5.55
- Bid/Ask
- $1.68 / $1.72
- Shares Outstanding
- 119.61M
- Market Cap
- $199.49M
- Volume/Avg
- 23,155 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 56
Valuation
Metric | PYXS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.25 |
Price/Sales | 9.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PYXS |
|---|---|
Quick Ratio | 2.79 |
Current Ratio | 2.96 |
Interest Coverage | — |
Quick Ratio
PYXS
Profitability
Metric | PYXS |
|---|---|
Return on Assets (Normalized) | −100.67% |
Return on Equity (Normalized) | −191.92% |
Return on Invested Capital (Normalized) | −135.37% |
Return on Assets
PYXS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|N#^H^?n | LOCK|%&#T | $138B | |||
| Moderna Inc MRNA | LOCK|jnN%jrw | LOCK|V< | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|hcmRnB | LOCK|?&M@C | $93B | |||
| argenx SE ADR ARGX | LOCK|Ljb!$! | LOCK|F@y | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|MN>>d$ | LOCK|M$ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|$y&r>syG | LOCK|qPx@w | $30B | |||
| Incyte Corp INCY | LOCK|dX?KfK< | LOCK|ZG! | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!FPK?d | LOCK|QZG | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%Hf@^< | LOCK|&z%?Z | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|R$^XsVy | LOCK|hnh | $15B |
United States